View ValuationCell Biotech 将来の成長Future 基準チェック /06現在、 Cell Biotechの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長24.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updates分析記事 • May 24Cell Biotech's (KOSDAQ:049960) Weak Earnings May Only Reveal A Part Of The Whole PictureA lackluster earnings announcement from Cell Biotech Co., Ltd. ( KOSDAQ:049960 ) last week didn't sink the stock price...New Risk • May 24New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 21% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (21% accrual ratio). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₩123.7b market cap, or US$81.4m).New Risk • Mar 27New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 19% Last year net profit margin: 30% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (19% net profit margin). Market cap is less than US$100m (₩98.4b market cap, or US$65.2m).お知らせ • Feb 26Cell Biotech Co., Ltd., Annual General Meeting, Mar 26, 2026Cell Biotech Co., Ltd., Annual General Meeting, Mar 26, 2026, at 09:30 Tokyo Standard Time. Location: conference room, 50, aegibong-ro 409beon-gil, wolgot-myeo, gyeonggi-do, gimpo South KoreaUpcoming Dividend • Dec 22Upcoming dividend of ₩450 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 03 April 2026. Payout ratio is a comfortable 24% and this is well supported by cash flows. Trailing yield: 3.3%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.6%).分析記事 • Nov 21Cell Biotech's (KOSDAQ:049960) Solid Earnings May Rest On Weak FoundationsThe recent earnings posted by Cell Biotech Co., Ltd. ( KOSDAQ:049960 ) were solid, but the stock didn't move as much as...Reported Earnings • Nov 20Third quarter 2025 earnings released: EPS: ₩504 (vs ₩142 in 3Q 2024)Third quarter 2025 results: EPS: ₩504 (up from ₩142 in 3Q 2024). Revenue: ₩15.4b (up 26% from 3Q 2024). Net income: ₩3.45b (up 256% from 3Q 2024). Profit margin: 23% (up from 8.0% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Nov 10Now 21% overvaluedOver the last 90 days, the stock has fallen 7.1% to ₩11,850. The fair value is estimated to be ₩9,797, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 11%.分析記事 • Nov 09Cell Biotech (KOSDAQ:049960) Has Affirmed Its Dividend Of ₩450.00Cell Biotech Co., Ltd.'s ( KOSDAQ:049960 ) investors are due to receive a payment of ₩450.00 per share on 3rd of April...Declared Dividend • Nov 08Dividend of ₩450 announcedDividend of ₩450 is the same as last year. Ex-date: 29th December 2025 Payment date: 3rd April 2026 Dividend yield will be 3.8%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is well covered by both earnings (30% earnings payout ratio) and cash flows (32% cash payout ratio). The dividend has decreased over the past 66 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 11% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • Nov 07Cell Biotech Co., Ltd. announces Annual dividend, payable on April 03, 2026Cell Biotech Co., Ltd. announced Annual dividend of KRW 450.0000 per share payable on April 03, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.Buy Or Sell Opportunity • Oct 01Now 21% overvaluedOver the last 90 days, the stock has fallen 3.7% to ₩12,520. The fair value is estimated to be ₩10,388, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 11%.Reported Earnings • May 21First quarter 2025 earnings released: EPS: ₩302 (vs ₩477 in 1Q 2024)First quarter 2025 results: EPS: ₩302 (down from ₩477 in 1Q 2024). Revenue: ₩11.2b (down 14% from 1Q 2024). Net income: ₩2.07b (down 37% from 1Q 2024). Profit margin: 18% (down from 25% in 1Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.分析記事 • Mar 27We Think That There Are Some Issues For Cell Biotech (KOSDAQ:049960) Beyond Its Promising EarningsCell Biotech Co., Ltd.'s ( KOSDAQ:049960 ) healthy profit numbers didn't contain any surprises for investors. We...お知らせ • Feb 28Cell Biotech Co., Ltd., Annual General Meeting, Mar 27, 2025Cell Biotech Co., Ltd., Annual General Meeting, Mar 27, 2025, at 09:30 Tokyo Standard Time. Location: conference room, 50, aegibong-ro 409beon-gil, wolgot-myeon, gyeonggi-do, gimpo South KoreaUpcoming Dividend • Dec 20Upcoming dividend of ₩450 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 03 April 2025. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 3.2%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (0.5%).New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₩98.8b market cap, or US$68.8m).分析記事 • Aug 24Shareholders Will Be Pleased With The Quality of Cell Biotech's (KOSDAQ:049960) EarningsCell Biotech Co., Ltd. ( KOSDAQ:049960 ) just reported healthy earnings but the stock price didn't move much. Investors...Buy Or Sell Opportunity • Aug 07Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 6.0% to ₩13,140. The fair value is estimated to be ₩10,918, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.0% over the last 3 years. Earnings per share has declined by 4.6%.Valuation Update With 7 Day Price Move • Jul 10Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₩16,280, the stock trades at a trailing P/E ratio of 16.6x. Average trailing P/E is 22x in the Biotechs industry in South Korea. Total loss to shareholders of 10% over the past three years.Reported Earnings • Mar 22Full year 2023 earnings released: EPS: ₩921 (vs ₩1,201 in FY 2022)Full year 2023 results: EPS: ₩921 (down from ₩1,201 in FY 2022). Revenue: ₩53.8b (up 6.5% from FY 2022). Net income: ₩6.30b (down 24% from FY 2022). Profit margin: 12% (down from 16% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Mar 18Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 14% to ₩12,820. The fair value is estimated to be ₩10,573, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.5% over the last 3 years. Earnings per share has grown by 7.1%.Buy Or Sell Opportunity • Feb 06Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 6.9% to ₩12,010. The fair value is estimated to be ₩9,783, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.5% over the last 3 years. Earnings per share has grown by 7.1%.Buy Or Sell Opportunity • Jan 22Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 6.9% to ₩11,850. The fair value is estimated to be ₩9,783, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.5% over the last 3 years. Earnings per share has grown by 7.1%.Upcoming Dividend • Dec 20Upcoming dividend of ₩450 per share at 4.0% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 01 April 2024. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 4.0%. Within top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (0.7%).New Risk • Nov 21New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 24% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Dividend per share is over 18x earnings per share. Cash payout ratio: 100% Earnings have declined by 20% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.3% net profit margin). Market cap is less than US$100m (₩75.8b market cap, or US$58.7m).Reported Earnings • May 21First quarter 2023 earnings released: EPS: ₩417 (vs ₩434 in 1Q 2022)First quarter 2023 results: EPS: ₩417 (down from ₩434 in 1Q 2022). Revenue: ₩12.8b (up 6.2% from 1Q 2022). Net income: ₩2.86b (down 5.1% from 1Q 2022). Profit margin: 22% (down from 25% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Buying Opportunity • Apr 07Now 20% undervaluedOver the last 90 days, the stock is up 17%. The fair value is estimated to be ₩18,778, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 2.7% over the last 3 years. Earnings per share has grown by 30%.Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩14,900, the stock trades at a trailing P/E ratio of 12.3x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 12% over the past three years.Reported Earnings • Mar 19Full year 2022 earnings released: EPS: ₩1,201 (vs ₩1,468 in FY 2021)Full year 2022 results: EPS: ₩1,201 (down from ₩1,468 in FY 2021). Revenue: ₩50.5b (up 7.8% from FY 2021). Net income: ₩8.28b (down 20% from FY 2021). Profit margin: 16% (down from 22% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Dec 21Upcoming dividend of ₩450 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 07 April 2023. Payout ratio is a comfortable 21% and this is well supported by cash flows. Trailing yield: 3.5%. Within top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (0.7%).Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Jun 17Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩12,650, the stock trades at a trailing P/E ratio of 8.2x. Average trailing P/E is 23x in the Biotechs industry in South Korea. Total loss to shareholders of 36% over the past three years.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Upcoming Dividend • Dec 22Upcoming dividend of ₩450 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 31 March 2022. Payout ratio is a comfortable 53% and this is well supported by cash flows. Trailing yield: 2.4%. Within top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%).分析記事 • May 05Factors Income Investors Should Consider Before Adding Cell Biotech Co., Ltd. (KOSDAQ:049960) To Their PortfolioIs Cell Biotech Co., Ltd. ( KOSDAQ:049960 ) a good dividend stock? How can we tell? Dividend paying companies with...分析記事 • Mar 18Is Cell Biotech Co., Ltd.'s (KOSDAQ:049960) Recent Price Movement Underpinned By Its Weak Fundamentals?With its stock down 6.9% over the past three months, it is easy to disregard Cell Biotech (KOSDAQ:049960). It is...分析記事 • Feb 25A Look At Cell Biotech's (KOSDAQ:049960) Share Price ReturnsStatistically speaking, long term investing is a profitable endeavour. But that doesn't mean long term investors can...Is New 90 Day High Low • Feb 24New 90-day low: ₩18,300The company is down 4.0% from its price of ₩19,000 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 7.0% over the same period.分析記事 • Feb 04Key Things To Watch Out For If You Are After Cell Biotech Co., Ltd.'s (KOSDAQ:049960) 3.2% DividendDividend paying stocks like Cell Biotech Co., Ltd. ( KOSDAQ:049960 ) tend to be popular with investors, and for good...分析記事 • Jan 14Is Cell Biotech Co., Ltd. (KOSDAQ:049960) Popular Amongst Insiders?If you want to know who really controls Cell Biotech Co., Ltd. ( KOSDAQ:049960 ), then you'll have to look at the...分析記事 • Dec 24Don't Race Out To Buy Cell Biotech Co., Ltd. (KOSDAQ:049960) Just Because It's Going Ex-DividendRegular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Cell Biotech...Is New 90 Day High Low • Dec 23New 90-day high: ₩21,850The company is up 48% from its price of ₩14,750 on 24 September 2020. The South Korean market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 14% over the same period.Upcoming Dividend • Dec 22Upcoming Dividend of ₩600 Per ShareWill be paid on the 31st of March to those who are registered shareholders by the 29th of December. The trailing yield of 2.9% is in the top quartile of South Korean dividend payers (2.6%), and it is higher than industry peers (0.3%).分析記事 • Dec 13Cell Biotech Co., Ltd.'s (KOSDAQ:049960) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?Most readers would already be aware that Cell Biotech's (KOSDAQ:049960) stock increased significantly by 33% over the...Is New 90 Day High Low • Dec 07New 90-day high: ₩20,500The company is up 25% from its price of ₩16,400 on 08 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 7.0% over the same period.分析記事 • Nov 18Reflecting on Cell Biotech's (KOSDAQ:049960) Share Price Returns Over The Last Five YearsCell Biotech Co., Ltd. (KOSDAQ:049960) shareholders should be happy to see the share price up 23% in the last quarter...Is New 90 Day High Low • Nov 11New 90-day high: ₩17,600The company is up 8.0% from its price of ₩16,350 on 13 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 5.0% over the same period.お知らせ • Sep 21Cell Biotech Co., Ltd.(KOSDAQ:A049960) dropped from S&P Global BMI IndexCell Biotech Co., Ltd.(KOSDAQ:A049960) dropped from S&P Global BMI Index このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Cell Biotech は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A049960 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202656,49413,4075,96113,225N/A12/31/202553,12610,1258,00711,109N/A9/30/202550,64912,5928,35511,622N/A6/30/202547,45610,1129,63110,961N/A3/31/202548,10413,93516,39917,574N/A12/31/202449,91315,12718,02419,267N/A9/30/202452,60010,97418,06419,107N/A6/30/202454,09712,96617,42618,309N/A3/31/202453,9806,7089,11810,045N/A12/31/202353,7876,3046,1407,815N/A9/30/202352,7511663,0735,128N/A6/30/202351,5092,7366,3529,333N/A3/31/202351,2728,1283,7586,816N/A12/31/202250,5268,28110,14112,814N/A9/30/202248,75414,64211,53813,660N/A6/30/202249,08112,99711,83813,137N/A3/31/202248,32810,63217,77918,913N/A12/31/202146,87310,38314,07014,892N/A9/30/202145,7616,0326,7027,815N/A6/30/202144,1963,2707,7109,220N/A3/31/202144,1562,9427,3289,763N/A12/31/202045,5823,1896,4719,564N/A9/30/202046,9905,9005,8619,984N/A6/30/202046,3336,472-1,1474,866N/A3/31/202046,5828,017-5,3053,626N/A12/31/201945,9607,231N/A10,231N/A9/30/201949,34611,379N/A14,714N/A6/30/201953,47313,585N/A16,896N/A3/31/201958,13616,544N/A17,346N/A12/31/201862,54419,384N/A13,976N/A9/30/201860,32416,525N/A23,491N/A6/30/201861,30117,865N/A20,963N/A3/31/201862,29519,802N/A24,204N/A12/31/201761,05718,198N/A22,528N/A9/30/201762,70620,756N/A15,812N/A6/30/201758,93718,581N/A19,302N/A3/31/201757,15017,071N/A15,987N/A12/31/201658,27618,499N/A17,991N/A9/30/201655,04817,719N/A21,522N/A6/30/201657,41821,705N/A25,873N/A3/31/201655,23020,603N/A21,743N/A12/31/201549,50517,505N/A18,236N/A9/30/201549,29116,582N/A13,263N/A6/30/201544,99712,474N/A5,812N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A049960の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A049960の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A049960の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A049960の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A049960の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A049960の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/15 17:17終値2026/06/15 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cell Biotech Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Young Ok KimDAOL Investment & Securities Co., Ltd.Hyuk Jin YoonEugene Investment & Securities Co Ltd.Sung Hwan ChoiKyobo Securities Co., Ltd5 その他のアナリストを表示
分析記事 • May 24Cell Biotech's (KOSDAQ:049960) Weak Earnings May Only Reveal A Part Of The Whole PictureA lackluster earnings announcement from Cell Biotech Co., Ltd. ( KOSDAQ:049960 ) last week didn't sink the stock price...
New Risk • May 24New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 21% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (21% accrual ratio). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₩123.7b market cap, or US$81.4m).
New Risk • Mar 27New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 19% Last year net profit margin: 30% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (19% net profit margin). Market cap is less than US$100m (₩98.4b market cap, or US$65.2m).
お知らせ • Feb 26Cell Biotech Co., Ltd., Annual General Meeting, Mar 26, 2026Cell Biotech Co., Ltd., Annual General Meeting, Mar 26, 2026, at 09:30 Tokyo Standard Time. Location: conference room, 50, aegibong-ro 409beon-gil, wolgot-myeo, gyeonggi-do, gimpo South Korea
Upcoming Dividend • Dec 22Upcoming dividend of ₩450 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 03 April 2026. Payout ratio is a comfortable 24% and this is well supported by cash flows. Trailing yield: 3.3%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.6%).
分析記事 • Nov 21Cell Biotech's (KOSDAQ:049960) Solid Earnings May Rest On Weak FoundationsThe recent earnings posted by Cell Biotech Co., Ltd. ( KOSDAQ:049960 ) were solid, but the stock didn't move as much as...
Reported Earnings • Nov 20Third quarter 2025 earnings released: EPS: ₩504 (vs ₩142 in 3Q 2024)Third quarter 2025 results: EPS: ₩504 (up from ₩142 in 3Q 2024). Revenue: ₩15.4b (up 26% from 3Q 2024). Net income: ₩3.45b (up 256% from 3Q 2024). Profit margin: 23% (up from 8.0% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Nov 10Now 21% overvaluedOver the last 90 days, the stock has fallen 7.1% to ₩11,850. The fair value is estimated to be ₩9,797, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 11%.
分析記事 • Nov 09Cell Biotech (KOSDAQ:049960) Has Affirmed Its Dividend Of ₩450.00Cell Biotech Co., Ltd.'s ( KOSDAQ:049960 ) investors are due to receive a payment of ₩450.00 per share on 3rd of April...
Declared Dividend • Nov 08Dividend of ₩450 announcedDividend of ₩450 is the same as last year. Ex-date: 29th December 2025 Payment date: 3rd April 2026 Dividend yield will be 3.8%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is well covered by both earnings (30% earnings payout ratio) and cash flows (32% cash payout ratio). The dividend has decreased over the past 66 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 11% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • Nov 07Cell Biotech Co., Ltd. announces Annual dividend, payable on April 03, 2026Cell Biotech Co., Ltd. announced Annual dividend of KRW 450.0000 per share payable on April 03, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.
Buy Or Sell Opportunity • Oct 01Now 21% overvaluedOver the last 90 days, the stock has fallen 3.7% to ₩12,520. The fair value is estimated to be ₩10,388, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 11%.
Reported Earnings • May 21First quarter 2025 earnings released: EPS: ₩302 (vs ₩477 in 1Q 2024)First quarter 2025 results: EPS: ₩302 (down from ₩477 in 1Q 2024). Revenue: ₩11.2b (down 14% from 1Q 2024). Net income: ₩2.07b (down 37% from 1Q 2024). Profit margin: 18% (down from 25% in 1Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
分析記事 • Mar 27We Think That There Are Some Issues For Cell Biotech (KOSDAQ:049960) Beyond Its Promising EarningsCell Biotech Co., Ltd.'s ( KOSDAQ:049960 ) healthy profit numbers didn't contain any surprises for investors. We...
お知らせ • Feb 28Cell Biotech Co., Ltd., Annual General Meeting, Mar 27, 2025Cell Biotech Co., Ltd., Annual General Meeting, Mar 27, 2025, at 09:30 Tokyo Standard Time. Location: conference room, 50, aegibong-ro 409beon-gil, wolgot-myeon, gyeonggi-do, gimpo South Korea
Upcoming Dividend • Dec 20Upcoming dividend of ₩450 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 03 April 2025. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 3.2%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (0.5%).
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₩98.8b market cap, or US$68.8m).
分析記事 • Aug 24Shareholders Will Be Pleased With The Quality of Cell Biotech's (KOSDAQ:049960) EarningsCell Biotech Co., Ltd. ( KOSDAQ:049960 ) just reported healthy earnings but the stock price didn't move much. Investors...
Buy Or Sell Opportunity • Aug 07Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 6.0% to ₩13,140. The fair value is estimated to be ₩10,918, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.0% over the last 3 years. Earnings per share has declined by 4.6%.
Valuation Update With 7 Day Price Move • Jul 10Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₩16,280, the stock trades at a trailing P/E ratio of 16.6x. Average trailing P/E is 22x in the Biotechs industry in South Korea. Total loss to shareholders of 10% over the past three years.
Reported Earnings • Mar 22Full year 2023 earnings released: EPS: ₩921 (vs ₩1,201 in FY 2022)Full year 2023 results: EPS: ₩921 (down from ₩1,201 in FY 2022). Revenue: ₩53.8b (up 6.5% from FY 2022). Net income: ₩6.30b (down 24% from FY 2022). Profit margin: 12% (down from 16% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Mar 18Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 14% to ₩12,820. The fair value is estimated to be ₩10,573, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.5% over the last 3 years. Earnings per share has grown by 7.1%.
Buy Or Sell Opportunity • Feb 06Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 6.9% to ₩12,010. The fair value is estimated to be ₩9,783, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.5% over the last 3 years. Earnings per share has grown by 7.1%.
Buy Or Sell Opportunity • Jan 22Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 6.9% to ₩11,850. The fair value is estimated to be ₩9,783, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.5% over the last 3 years. Earnings per share has grown by 7.1%.
Upcoming Dividend • Dec 20Upcoming dividend of ₩450 per share at 4.0% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 01 April 2024. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 4.0%. Within top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (0.7%).
New Risk • Nov 21New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 24% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Dividend per share is over 18x earnings per share. Cash payout ratio: 100% Earnings have declined by 20% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.3% net profit margin). Market cap is less than US$100m (₩75.8b market cap, or US$58.7m).
Reported Earnings • May 21First quarter 2023 earnings released: EPS: ₩417 (vs ₩434 in 1Q 2022)First quarter 2023 results: EPS: ₩417 (down from ₩434 in 1Q 2022). Revenue: ₩12.8b (up 6.2% from 1Q 2022). Net income: ₩2.86b (down 5.1% from 1Q 2022). Profit margin: 22% (down from 25% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Buying Opportunity • Apr 07Now 20% undervaluedOver the last 90 days, the stock is up 17%. The fair value is estimated to be ₩18,778, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 2.7% over the last 3 years. Earnings per share has grown by 30%.
Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩14,900, the stock trades at a trailing P/E ratio of 12.3x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 12% over the past three years.
Reported Earnings • Mar 19Full year 2022 earnings released: EPS: ₩1,201 (vs ₩1,468 in FY 2021)Full year 2022 results: EPS: ₩1,201 (down from ₩1,468 in FY 2021). Revenue: ₩50.5b (up 7.8% from FY 2021). Net income: ₩8.28b (down 20% from FY 2021). Profit margin: 16% (down from 22% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Dec 21Upcoming dividend of ₩450 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 07 April 2023. Payout ratio is a comfortable 21% and this is well supported by cash flows. Trailing yield: 3.5%. Within top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (0.7%).
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Jun 17Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩12,650, the stock trades at a trailing P/E ratio of 8.2x. Average trailing P/E is 23x in the Biotechs industry in South Korea. Total loss to shareholders of 36% over the past three years.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Upcoming Dividend • Dec 22Upcoming dividend of ₩450 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 31 March 2022. Payout ratio is a comfortable 53% and this is well supported by cash flows. Trailing yield: 2.4%. Within top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%).
分析記事 • May 05Factors Income Investors Should Consider Before Adding Cell Biotech Co., Ltd. (KOSDAQ:049960) To Their PortfolioIs Cell Biotech Co., Ltd. ( KOSDAQ:049960 ) a good dividend stock? How can we tell? Dividend paying companies with...
分析記事 • Mar 18Is Cell Biotech Co., Ltd.'s (KOSDAQ:049960) Recent Price Movement Underpinned By Its Weak Fundamentals?With its stock down 6.9% over the past three months, it is easy to disregard Cell Biotech (KOSDAQ:049960). It is...
分析記事 • Feb 25A Look At Cell Biotech's (KOSDAQ:049960) Share Price ReturnsStatistically speaking, long term investing is a profitable endeavour. But that doesn't mean long term investors can...
Is New 90 Day High Low • Feb 24New 90-day low: ₩18,300The company is down 4.0% from its price of ₩19,000 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 7.0% over the same period.
分析記事 • Feb 04Key Things To Watch Out For If You Are After Cell Biotech Co., Ltd.'s (KOSDAQ:049960) 3.2% DividendDividend paying stocks like Cell Biotech Co., Ltd. ( KOSDAQ:049960 ) tend to be popular with investors, and for good...
分析記事 • Jan 14Is Cell Biotech Co., Ltd. (KOSDAQ:049960) Popular Amongst Insiders?If you want to know who really controls Cell Biotech Co., Ltd. ( KOSDAQ:049960 ), then you'll have to look at the...
分析記事 • Dec 24Don't Race Out To Buy Cell Biotech Co., Ltd. (KOSDAQ:049960) Just Because It's Going Ex-DividendRegular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Cell Biotech...
Is New 90 Day High Low • Dec 23New 90-day high: ₩21,850The company is up 48% from its price of ₩14,750 on 24 September 2020. The South Korean market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 14% over the same period.
Upcoming Dividend • Dec 22Upcoming Dividend of ₩600 Per ShareWill be paid on the 31st of March to those who are registered shareholders by the 29th of December. The trailing yield of 2.9% is in the top quartile of South Korean dividend payers (2.6%), and it is higher than industry peers (0.3%).
分析記事 • Dec 13Cell Biotech Co., Ltd.'s (KOSDAQ:049960) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?Most readers would already be aware that Cell Biotech's (KOSDAQ:049960) stock increased significantly by 33% over the...
Is New 90 Day High Low • Dec 07New 90-day high: ₩20,500The company is up 25% from its price of ₩16,400 on 08 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 7.0% over the same period.
分析記事 • Nov 18Reflecting on Cell Biotech's (KOSDAQ:049960) Share Price Returns Over The Last Five YearsCell Biotech Co., Ltd. (KOSDAQ:049960) shareholders should be happy to see the share price up 23% in the last quarter...
Is New 90 Day High Low • Nov 11New 90-day high: ₩17,600The company is up 8.0% from its price of ₩16,350 on 13 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 5.0% over the same period.
お知らせ • Sep 21Cell Biotech Co., Ltd.(KOSDAQ:A049960) dropped from S&P Global BMI IndexCell Biotech Co., Ltd.(KOSDAQ:A049960) dropped from S&P Global BMI Index